Company profile
CBD of Denver, Inc.
OTC: CBDD · Healthcare · Drug Manufacturers - Specialty & Generic
#923 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
34DFH 36DQ —GM 26SS 42
v0.1 · 45/100 weight · provisional
↑ listing tenure, operating margin · ↓ workforce scale, balance-sheet leverage
Methodology →Revenue TTM
$591.3k
Rev growth YoY (TTM)
-84.2%
Net income (FY)
-$290.1k
Employees
2
as of 2026-08-25
Market cap
$1.1M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$599.4k$599.4k2025
Net income-$290.1k-$290.1k2025
Operating income-$18.1k-$18.1k2025
Total assets$40.8k$40.8k2024
Liabilities$1.4M$1.4M2024
Equity-$1.3M-$1.3M2024
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CBD of Denver, Inc.’s revenue?
CBD of Denver, Inc. booked $599.4k in FY2025 revenue, contracting 84% year over year — slower than 89% of Healthcare companies we track, at a -48.4% net margin.
Peers · Healthcare
NovelStem International Corp.37DTheralink Technologies, Inc.——Vaccinex, Inc.——Cardiff Oncology, Inc.53DPMGC Holdings Inc.29DGrapefruit USA, Inc.——Neighbors
Arapahoe →Key facts
CEOJan Schwager
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCentennial, CO
ExchangeOTC: CBDD
Employees2
IPO date1996-05-15
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.